drugset / Trial / NCT00281567

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT00281567

Phase 3 Completed 76 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.

Timeline

Start
2002-08
Primary completion
2003-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 5 ug Inhaled
Subject Tiotropium Other / unclassified 10 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled